| Filed On | Filing |
|---|---|
| 23 Oct 2026 | SCHEDULE 13D |
| 29 Sep 2026 |
Form 4: Seshadri Vishwas, Director
Sold 19,608 shares ($101K) |
| 29 Sep 2026 |
Form 4: Vazzano Joseph Walter, Chief Financial Officer
Sold 9,191 shares ($47.4K) |
| 29 Sep 2026 |
Form 4: O'Malley Brendan M., SVP, Chief Legal Officer
Sold 6,727 shares ($34.7K) |
| 29 Sep 2026 |
Form 4: Vasanthavada Madhav, Chief Commercial Officer
Sold 4,902 shares ($25.3K) |
| 29 Sep 2026 | 144 |
| 29 Sep 2026 | 144 |
| 29 Sep 2026 | 144 |
| 29 Sep 2026 | 144 |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Abeona Therapeutics Inc. is furnishing in this Current Report on Form 8-K an updated investor presentation (the “Investor Presentation”) that it expects to use, either in whole or in part, on September 15, 2026 at the H.C. Wainwright 28t... |
| 01 Sep 2026 |
Form 4: Alvino Mark, Director
Sold 15,000 shares ($88K) |
| 01 Sep 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 22 Jul 2026 |
Form 4: Vazzano Joseph Walter, Chief Financial Officer
Sold 1,478 shares ($9.65K) |
| 10 Jul 2026 | 424B3 |
| 09 Jul 2026 |
Form 4: Vazzano Joseph Walter, Chief Financial Officer
Sold 24,880 shares ($173K) |
| 09 Jul 2026 |
Form 4: Seshadri Vishwas, Director
Sold 67,971 shares ($473K) |
| 09 Jul 2026 |
Form 4: O'Malley Brendan M., SVP, Chief Legal Officer
Sold 12,050 shares ($83.9K) |
Loading...
